Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac Commercial Scale Bridging Study
NCT04617483Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of coronavac in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Geometric Mean Titer of neutralizing antibody. Started Oct 2020; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04617483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04617483.